|
gptkbp:instanceOf
|
gptkb:drug
amino acid derivative
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:R05CB01
|
|
gptkbp:CASNumber
|
616-91-1
|
|
gptkbp:chemicalFormula
|
C5H9NO3S
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
hypersensitivity to acetylcysteine
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
5.6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:flavor
|
slightly acidic
|
|
gptkbp:hasInChIKey
|
PWKSKIMOESPYIA-REOHCLBHSA-N
|
|
gptkbp:hasSMILES
|
CC(=O)N[C@@H](CS)C(=O)O
|
|
gptkbp:hasUNII
|
WYQ7N0BPYC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
N-acetylcysteine
|
|
gptkbp:IUPACName
|
(2R)-2-acetamido-3-sulfanylpropanoic acid
|
|
gptkbp:KEGGID
|
gptkb:D00221
|
|
gptkbp:legalStatus
|
prescription only (US)
|
|
gptkbp:mechanismOfAction
|
glutathione precursor
mucolytic agent
|
|
gptkbp:meltingPoint
|
109°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
163.19 g/mol
|
|
gptkbp:predecessor
|
glutathione
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL137
gptkb:DB06151
12035
11546
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
rash
anaphylactoid reactions
|
|
gptkbp:synonym
|
gptkb:Acetylcysteine
gptkb:Mucomyst
gptkb:NAC
Parvolex
|
|
gptkbp:usedAsAntidoteFor
|
acetaminophen poisoning
|
|
gptkbp:usedFor
|
gptkb:COVID-19_(investigational)
chronic obstructive pulmonary disease
cystic fibrosis
contrast-induced nephropathy (off-label)
mucolytic therapy
paracetamol overdose
psychiatric disorders (investigational)
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Antidotes
gptkb:NAC
gptkb:Antidote
|
|
gptkbp:bfsLayer
|
5
|